Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2012

Open Access 01-12-2012 | Research

Gene expression profiling of the synergy of 5-aza-2′-deoxycytidine and paclitaxel against renal cell carcinoma

Authors: Tiandong Han, Donghao Shang, Xiuhong Xu, Ye Tian

Published in: World Journal of Surgical Oncology | Issue 1/2012

Login to get access

Abstract

Background

Renal cell carcinoma (RCC) is one of the most common kidney cancers and is highly resistant to chemotherapy. We previously demonstrated that 5-aza-2′-deoxycytidine (DAC) could significantly increase the susceptibility of renal cell carcinoma (RCC) cells to paclitaxel (PTX) treatment in vitro, and showed the synergy of DAC and PTX against RCC. The purpose of this study is to investigated the gene transcriptional alteration and investigate possible molecular mechanism and pathways implicated in the synergy of DAC and PTX against RCC.

Methods

cDNA microarray was performed and coupled with real-time PCR to identify critical genes in the synergistic mechanism of both agents against RCC cells. Various patterns of gene expression were observed by cluster analysis. IPA software was used to analyze possible biological pathways and to explore the inter-relationships between interesting network genes.

Results

We found that lymphoid enhancer-binding factor 1 (LEF1), transforming growth factor β-induced (TGFBI), C-X-C motif ligand 5 (CXCL5) and myelocytomatosis viral related oncogene (c-myc) may play a pivotal role in the synergy of DAC and PTX. The PI3K/Akt pathway and other pathways associated with cyclins, DNA replication and cell cycle/mitotic regulation were also associated with the synergy of DAC and PTX against RCC.

Conclusion

The activation of PI3K/Akt-LEF1/β-catenin pathway could be suppressed synergistically by two agents and that PI3K/Akt-LEF1/β-catenin pathway is participated in the synergy of two agents.
Appendix
Available only for authorised users
Literature
1.
Mulders P, Brouwers A, Hulsbergen-van Der Kaa C, Van Lin E, Osanto S, De Mulder PH: ‘Guideline Renal cell carcinoma’. Ned Tijdschr Geneeskd. 2008, 152: 376-380.PubMed
2.
Yu DS, Chang SY, Ma CP: The expression of MDR-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines. Br J Urol. 1998, 82: 544-547. 10.1046/j.1464-410X.1998.00796.x.CrossRefPubMed
3.
Hartmann JT, Bokemeyer C: Chemotherapy for renal cell carcinoma. Anticancer Res. 1999, 19: 1541-1543.PubMed
4.
Ravaud A, Audhuy B, Gomez F, Escudier B, Chevreau C, Douillard JY, Caty A, Geoffrois L, Ferrero JM, Linassier C, Drevon M, Négrier S: Subcutaneous interleukin-2, interferonα-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter Phase II trial. J Clin Oncol. 1998, 16: 2728-2732.PubMed
5.
Atzpodien J, Kirchner H, Hanninen E, Deckert M, Fenner M, Poliwoda H: Interleukin-2 in combination with interferon-αand 5-fluorouracil for metastatic renal cell carcinoma. Eur J Cancer. 1993, Suppl 5: S6-8.CrossRef
6.
7.
Chalitchagorn K, Shuangshoti S, Hourpai N, Kongruttanachok N, Tangkijvanich P, Thong-ngam D, Voravud N, Sriuranpong V, Mutirangura A: Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene. 2004, 23: 8841-8846. 10.1038/sj.onc.1208137.CrossRefPubMed
8.
Christman JK: 5-Azacytidine and 5-aza-2′-deoxycitidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002, 21: 5483-5495. 10.1038/sj.onc.1205699.CrossRefPubMed
9.
Karpf AR, Moore BC, Ririe TO, Jones DA: Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2′-deoxycytidine. Mol Pharmacol. 2001, 59: 751-757.PubMed
10.
Kaufmann WK, Paules RS: DNA damage and cell cycle checkpoints. FASEB J. 1996, 10: 238-247.PubMed
11.
Karlsson-Rosenthal C, Millar JB: Cdc25: mechanisms of checkpoint inhibition and recovery. Trends Cell Biol. 2006, 16: 285-292. 10.1016/j.tcb.2006.04.002.CrossRefPubMed
12.
Wang TH, Wang HS, Soong YK: Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 2000, 88: 2619-2628. 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J.CrossRefPubMed
13.
Shang D, Ito N, Kamoto T, Ogawa O: Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel. Urology. 2007, 69: 1007-1012. 10.1016/j.urology.2007.02.026.CrossRefPubMed
14.
Berenbaum MC: A method for testing for synergy with any number of agents. J Infect Dis. 1978, 137: 122-130. 10.1093/infdis/137.2.122.CrossRefPubMed
15.
Cariello N, Romach E, Colton H, Ni H, Yoon L, Falls JG, Casey W, Creech D, Anderson SP, Benavides GR, Hoivik DJ, Brown R, Miller RT: Gene expression profiling of the PPAR-alpha agonist ciprofibrate in the cynomolgus monkey liver. Toxicol Sci. 2005, 88: 250-264. 10.1093/toxsci/kfi273.CrossRefPubMed
16.
Hattori K, Akaza H: New combination chemotherapy in urological cancers. Gan To Kagaku Ryoho. 2000, 27: 382-387.PubMed
17.
Gomyo Y, Sasaki J, Branch C, Roth JA, Mukhopadhyay T: 5-aza-2′-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells. Oncogene. 2004, 23: 6779-6787. 10.1038/sj.onc.1207381.CrossRefPubMed
18.
Kaminski R, Kozar K, Niderla J, Grzela T, Wilczynski G, Skierski JS, Koronkiewicz M, Jakobisiak M, Golab J: Demethylating agent 5-aza-2′-deoxycytidine enhances expression of TNFRI and promotes TNF-mediated apoptosis in vitro and in vivo. Oncol Rep. 2004, 12: 509-516.PubMed
19.
Alleman WG, Tabios RL, Chandramouli GV, Aprelikova ON, Torres-Cabala C, Mendoza A, Rogers C, Sopko NA, Linehan WM, Vasselli JR: The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2′-deoxycytidine. Clin Cancer Res. 2004, 10: 7011-7021. 10.1158/1078-0432.CCR-04-0516.CrossRefPubMed
20.
Shi H, Wei SH, Leu YW, Rahmatpanah F, Liu JC, Yan PS, Nephew KP, Huang TH: Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res. 2003, 63: 2164-2171.PubMed
21.
Zhu WG, Hileman T, Ke Y, Wang P, Lu S, Duan W, Dai Z, Tong T, Villalona-Calero MA, Plass C, Otterson GA: 5-aza-2′-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem. 2004, 279: 15161-15166. 10.1074/jbc.M311703200.CrossRefPubMed
22.
Travis A, Amsterdam A, Belanger C, Grosschedl R: LEF-1, a gene encoding a lymphoid-specific protein with an HMG domain, regulates T-cell receptor alpha enhancer function. Genes Dev. 1991, 5: 880-894. 10.1101/gad.5.5.880.CrossRefPubMed
23.
Waterman ML, Fischer WH, Jones KA: A thymus-specific member of the HMG protein family regulates the human T cell receptor C alpha enhancer. Genes Dev. 1991, 5: 656-669. 10.1101/gad.5.4.656.CrossRefPubMed
24.
Cadigan KM, Nusse R: Wnt signaling: a common theme in animal development. Genes Dev. 1997, 11: 3286-3305. 10.1101/gad.11.24.3286.CrossRefPubMed
25.
Bienz M, Clevers H: Linking colorectal cancer to Wnt signaling. Cell. 2000, 103: 311-320. 10.1016/S0092-8674(00)00122-7.CrossRefPubMed
26.
Nusse R: WNT targets: repression and activation. Trends Genet. 1999, 15: 1-3. 10.1016/S0168-9525(98)01634-5.CrossRefPubMed
27.
Eichhoff OM, Weeraratna A, Zipser MC, Denat L, Widmer DS, Xu M, Kriegl L, Kirchner T, Larue L, Dummer R, Hoek KS: Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching. Pigment Cell Melanoma Res. 2011, 24: 631-642. 10.1111/j.1755-148X.2011.00871.x.CrossRefPubMed
28.
Li TW, Ting JH, Yokoyama NN, Bernstein A, van de Wetering M, Waterman ML: Wnt activation and alternative promoter repression of LEF1 in colon cancer. Mol Cell Biol. 2006, 26: 5284-5299. 10.1128/MCB.00105-06.PubMedCentralCrossRefPubMed
29.
Shang D, Liu Y, Xu X, Han T, Tian Y: 5-aza-2′-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel by decreasing LEF1/phospho-β-catenin expression. Cancer Letter. 2011, 311: 230-236. 10.1016/j.canlet.2011.08.012.CrossRef
30.
Kim JE, Jeong HW, Nam JO, Lee BH, Choi JY, Park RW, Park JY, Kim IS: Identification of motifs in the fasciclin domains of the transforming growth factor-beta-induced matrix protein betaig-h3 that interact with the alphavbeta5 integrin. J Biol Chem. 2002, 277: 46159-46165. 10.1074/jbc.M207055200.CrossRefPubMed
31.
Park SW, Bae JS, Kim KS, Park SH, Lee BH, Choi JY, Park JY, Ha SW, Kim YL, Kwon TH, Kim IS, Park RW: Beta ig-h3 promotes renal proximal tubular epithelial cell adhesion, migration and proliferation through the interaction with alpha3beta1 integrin. Exp Mol Med. 2004, 36: 211-219.CrossRefPubMed
32.
Skonier J, Neubauer M, Madisen L, Bennett K, Plowman GD, Purchio AF: cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta. DNA Cell Biol. 1992, 11: 511-522. 10.1089/dna.1992.11.511.CrossRefPubMed
33.
Ivanov SV, Ivanova AV, Salnikow K, Timofeeva O, Subramaniam M, Lerman MI: Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors. Biochem Biophys Res Commun. 2008, 370: 536-540. 10.1016/j.bbrc.2008.03.066.PubMedCentralCrossRefPubMed
34.
Shang D, Liu Y, Yang P, Chen Y, Tian Y: TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor. Urology. 2012, 79: 966.e1-966.e7. 10.1016/j.urology.2011.12.011.CrossRef
35.
Wong YF, Cheung TH, Lo KW, Yim SF, Siu NS, Chan SC, Ho TW, Wong KW, Yu MY, Wang VW, Li C, Gardner GJ, Bonome T, Johnson WB, Smith DI, Chung TK, Birrer MJ: Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling. Oncogene. 2007, 26: 1971-1982. 10.1038/sj.onc.1209986.CrossRefPubMed
36.
Park JY, Park KH, Bang S, Kim MH, Lee JE, Gang J, Koh SS, Song SY: CXCL5 overexpression is associated with late stage gastric cancer. J Cancer Res Clin Oncol. 2007, 133: 835-840. 10.1007/s00432-007-0225-x.CrossRefPubMed
37.
Napoli C, Lerman LO, de Nigris F, Sica V: c-myc oncoprotein: a dual pathogenic role in neoplasia and cardiovascular diseases?. Neoplasia. 2002, 3: 185-190.CrossRef
38.
Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN, Golub TR: Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci. 2000, 97: 3260-3265. 10.1073/pnas.97.7.3260.PubMedCentralCrossRefPubMed
39.
Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC: Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res. 1993, 53: 3869-3873.PubMed
40.
Macoska JA, Trybus TM, Benson PD, Sakr WA, Grignon DJ, Wojno KD, Pietruk T, Powell IJ: Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. Cancer Res. 1995, 55: 5390-5395.PubMed
41.
Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ, Jenkins RB: Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst. 1999, 91: 1574-1580. 10.1093/jnci/91.18.1574.CrossRefPubMed
42.
Christoph F, Schmidt B, Schulz W, Schulz WA: Over-expression and amplification of the c-myc gene in human urothelial carcinoma. Int J Cancer. 1999, 84: 169-173. 10.1002/(SICI)1097-0215(19990420)84:2<169::AID-IJC13>3.0.CO;2-F.CrossRefPubMed
43.
Furge KA, Chen J, Koeman J, Swiatek P, Dykema K, Lucin K, Kahnoski R, Yang XJ, Teh BT: Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res. 2007, 67: 3171-3176. 10.1158/0008-5472.CAN-06-4571.CrossRefPubMed
44.
Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP, Sauter G: Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res. 1999, 5: 1966-1975.PubMed
45.
Strefford JC, Stasevich I, Lane TM, Lu YJ, Oliver T, Young BD: A combination of molecular cytogenetic analyses reveals complex genetic alterations in conventional renal cell carcinoma. Cancer Genet Cytogenet. 2005, 159: 1-9. 10.1016/j.cancergencyto.2004.09.020.CrossRefPubMed
46.
Manna P, Jain SK: Hydrogen sulfide and L-cysteine increase phosphatidylinositol 3,4,5-trisphosphate (PIP3) and glucose utilization by inhibiting phosphatase and tensin homolog (PTEN) protein and activating phosphoinositide 3-kinase (PI3K)/serine/threonine protein kinase (AKT)/protein kinase Cζ/λ (PKCζ/λ) in 3T3l1 adipocytes. J Biol Chem. 2011, 286: 39848-39859. 10.1074/jbc.M111.270884.PubMedCentralCrossRefPubMed
Metadata
Title
Gene expression profiling of the synergy of 5-aza-2′-deoxycytidine and paclitaxel against renal cell carcinoma
Authors
Tiandong Han
Donghao Shang
Xiuhong Xu
Ye Tian
Publication date
01-12-2012
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2012
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-10-183

Other articles of this Issue 1/2012

World Journal of Surgical Oncology 1/2012 Go to the issue

Research

Two-year quality of life after free flap reconstruction in tumor-site discrepancy among Taiwanese with moderately advanced oral squamous cell carcinoma

Case report

A case of parosteal osteosarcoma with a rare complication of myositis ossificans

Research

The clinical significance of incidental intra-abdominal findings on positron emission tomography performed to investigate pulmonary nodules

Research

Nuclear BMI-1 expression in laryngeal carcinoma correlates with lymph node pathological status

Case report

A rare giant gastrointestinal stromal tumor of the stomach traversing the upper abdomen: a case report and literature review

Research

CT-guided percutaneous microwave ablation of pulmonary malignancies: Results in 69 cases